公开(公告)号：US20160250172A1

公开(公告)日：2016-09-01

申请号：US15057836

申请日：2016-03-01

Applicant: Biogen MA Inc.

Inventor： Susan Goelz ,  Katherine Dawson ,  Ralf Linker ,  Ralf Gold

IPC: A61K31/225 ,  A61K31/785 ,  A61K31/194

CPC classification number: A61K31/225 ,  A61K9/2072 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/194 ,  A61K31/785 ,  A61K38/02 ,  A61K38/215 ,  A61K2300/00

Abstract: Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: wherein R1 and R2 are independently selected from OH, O−, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.

Abstract translation: 提供治疗神经系统疾病的方法，例如由脱髓鞘和/或轴突损失（例如MS）表征的那些。 所述方法包括施用治疗有效量的至少一种式I化合物：其中R 1和R 2独立地选自OH，O-和（C 1-6）烷氧基，或其药学上可接受的盐; 和醋酸格拉默或干扰素-β。

公开(公告)号：US20180263946A1

公开(公告)日：2018-09-20

申请号：US15988568

申请日：2018-05-24

Applicant: Biogen MA Inc.

Inventor： David Goldman ,  Katherine Dawson ,  Ajay Nirula

IPC: A61K31/225 ,  A61K45/06 ,  A61K31/60 ,  A61K9/28 ,  A61K9/20 ,  A61K9/48 ,  A61K31/616 ,  A61K9/16

CPC classification number: A61K31/225 ,  A61K9/16 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2833 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/60 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

公开(公告)号：US20180021288A1

公开(公告)日：2018-01-25

申请号：US15644029

申请日：2017-07-07

Applicant: Biogen MA Inc.

Inventor： Susan Goelz ,  Katherine Dawson ,  Ralf Linker ,  Ralf Gold

IPC: A61K31/225 ,  A61K31/194 ,  A61K9/28 ,  A61K31/785 ,  A61K38/02 ,  A61K9/48 ,  A61K38/21 ,  A61K9/20

CPC classification number: A61K31/225 ,  A61K9/2072 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/194 ,  A61K31/785 ,  A61K38/02 ,  A61K38/215 ,  A61K2300/00

Abstract: Methods of treating neurological disorders, e.g., those characterized by demyelination and/or axonal loss (e.g., MS), are provided. The methods comprise administration of a therapeutically effective amount of at least one compound of Formula I: wherein R1 and R2 are independently selected from OH, O−, and (C1-6)alkoxy, or a pharmaceutically acceptable salt thereof; and either glatiramer acetate or interferon-beta.

公开(公告)号：US20200222354A1

公开(公告)日：2020-07-16

申请号：US16826938

申请日：2020-03-23

Applicant: Biogen MA Inc.

Inventor： David Goldman ,  Katherine Dawson ,  Ajay Nirula

IPC: A61K31/225 ,  A61K31/60 ,  A61K45/06 ,  A61K9/20 ,  A61K9/28 ,  A61K31/616 ,  A61K9/48 ,  A61K9/16

Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

公开(公告)号：US20180185319A1

公开(公告)日：2018-07-05

申请号：US15910745

申请日：2018-03-02

Applicant: Biogen MA Inc.

Inventor： David Goldman ,  Katherine Dawson ,  Ajay Nirula

IPC: A61K31/225 ,  A61K45/06 ,  A61K31/60 ,  A61K9/28 ,  A61K9/20 ,  A61K9/48 ,  A61K9/16 ,  A61K31/616

CPC classification number: A61K31/225 ,  A61K9/16 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2833 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/60 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.